Compare Pfizer Inc (PFE) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Pfizer Inc trades at $27.83 (market cap $158.56B), while Vanguard Total International Stock Index Fund ETF trades at $84.71 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 4.2× Pfizer Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Vanguard Total International Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| PFE | VXUS | |
|---|---|---|
Market Cap | $158.56B | $665.70B |
Volume | 44,138,282 | 4,864,744 |
Sector | Health | Sector/Thematic |
52-Week High | $29.02 | $88.41 |
52-Week Low | $23.67 | $72.17 |
Typical Hold Time | 158 Days | 55 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
VXUS trades at $84.78, down 1.19% with a bearish technical signal from moving averages. The ETF provides broad international stock exposure outside the U.S., with institutional buying interest noted in recent SEC filings. Technical indicators show neutral oscillators but bearish momentum signals from ADX readings.
The fund offers diversification benefits as a core international holding, though recent performance faces headwinds. Key risks include currency fluctuations and emerging market volatility. Long-term outlook remains positive for global equity exposure, supported by Vanguard's low-cost structure and comprehensive market coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
